Thursday, January 20, 2011

Imris Inc. (NASDAQ:IMRS) Great Story Early in Cycle

Imris Inc. (NASDAQ:IMRS) is a great opportunity for investors to get in early in the growth cycle, according to Canaccord Genuity, which believes they have transformative medical technology in their hands.

Canaccord says, "We believe IMRIS offers investors a rare opportunity to participate in a potentially transformative medical technology very early in its growth cycle. Following additional due diligence on the company, as well as a meeting with management, we are incrementally more confident about management’s ability to execute on a huge TAM opportunity. We believe the stock warrants a premium multiple to the small-cap med-tech peer group given its growth profile; therefore, we increase our target and reiterate our BUY/Best Idea stance on the stock."

Canaccord Genuity maintains a "Buy" rating on Imris Inc. (IMRS), which closed at $7.34, up $0.03, or 0.41 percent. Canaccord raised their price target on Imris from $9 to $10.50.

No comments: